54965-24-1 Tamoxifen citrate AKSci J10303
 
 
Loading Please Wait...
  J10303    
Tamoxifen citrate
, >98% (HPLC)
 
(Z)-1-(4-Dimethylaminoethoxyphenyl)-1,2-diphenyl-1-butene citrate
Istubal




IDENTITY
CAS Number:54965-24-1
MDL Number:MFCD00058321
MF:C32H37NO8
MW:563.64
EINECS:259-415-2
SPECIFICATIONS & PROPERTIES
Purity:>98% (HPLC)
Physical Form:White to off-white powder
Melting Point:140-147°C
Long-Term Storage:Store long-term at 2-8°C
UN #:Not hazmat

BIOLOGICAL INFO
Solubility:DMSO: 113mg/mL; H2O: <1mg/mL; EtOH: <1mg/mL
Application(s):Estrogen receptor antagonist
Form:Citrate

REVIEW

 Tamoxifen binds to estrogen receptors (ER), inducing a conformational change in the receptor. This results in a blockage or change in the expression of estrogen dependent genes. The prolonged binding of tamoxifen to the nuclear chromatin of these results in reduced DNA polymerase activity, impaired thymidine utilization, blockade of estradiol uptake, and decreased estrogen response. It is likely that tamoxifen interacts with other coactivators or corepressors in the tissue and binds with different estrogen receptors, ER-alpha or ER-beta, producing both estrogenic and antiestrogenic effects.

REFERENCES
[1]Jordan VC: Tamoxifen (ICI46,474) as a targeted therapy to treat and prevent breast cancer. Br J Pharmacol. 2006 Jan;147 Suppl 1:S269-76.
[2] Jordan VC: Fourteenth Gaddum Memorial Lecture. A current view of tamoxifen for the treatment and prevention of breast cancer. Br J Pharmacol. 1993 Oct;110(2):507-17.
[3] Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS: Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet. 2005 Jan 1-7;365(9453):60-2.
[4] Steiner AZ, Terplan M, Paulson RJ: Comparison of tamoxifen and clomiphene citrate for ovulation induction: a meta-analysis. Hum Reprod. 2005 Jun;20(6):1511-5. Epub 2005 Apr 21.

GHS

Pictograms

Signal Word
Danger

Hazard Statements
H302; H350; H360

Precautionary Statements
P201; P202; P264; P270; P281; P301+P312; P308+P313; P330; P405; P501


Current as of January 19, 2019


Download SDS

CATEGORIES

 APIs and Bioactives > Estrogen Receptor Modulators


PubChem